Press Releases

Press Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools.

Jun 02, 2016
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that Garo H. Armen, Ph.D., Chairman and CEO, and Robert B.
May 19, 2016
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced the appointment of Ulf Wiinberg to the Company’s Board of Directors.
Apr 28, 2016
Company to host conference call at 11am ET today LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company developing checkpoint antibodies and cancer vaccines, today provided a corporate update and reported financial results for the first quarter ended March 31,
Mar 30, 2016
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing checkpoint modulator antibodies and cancer vaccines, today announced participation at the following conferences: The 6 th  Annual William Blair and Maidstone Life Sciences conference “Cancer
Mar 01, 2016
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company developing checkpoint modulator antibodies and cancer vaccines, today announced that Garo Armen, Ph.D., Chairman and CEO, and Robert B. Stein, M.D., Ph.D., President, R&D at Agenus will present at the   Cowen
Jan 14, 2016
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunotherapy company developing innovative treatments for patients with cancer, announced that in connection with its acquisition of XOMA Corporation’s antibody manufacturing pilot plant it granted stock options and restricted
Jan 04, 2016
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immunotherapy company developing innovative treatments for patients with cancer, announced today that it has completed the previously announced acquisition of XOMA Corporation’s (NASDAQ: XOMA) antibody manufacturing pilot plant and
Dec 23, 2015
Offers the potential for rapid advancement of clinical programs and creation of new partnerships Novel class of cancer neoantigens further differentiate AutoSynVax™ vaccine platform LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunotherapy company developing innovative
Dec 01, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced that Robert B. Stein, MD, PhD, Chief Scientific Officer and Head of R&D at Agenus will present at the Oppenheimer 26 th  Annual
Nov 12, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), today announced additional details for the Company’s upcoming R&D update session to be held on Thursday, November 19, 2015, from 4:00 to 7:00 PM Eastern Time at the: St. Regis Hotel Penthouse Two East 55 th  Street at Fifth Avenue New
Oct 27, 2015
Corporate Update Conference Call at 11 am ET Today LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immunology company discovering and developing innovative treatments for cancers and other diseases, today announced its financial results for the third quarter ended September 30,
Oct 27, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immunology company discovering and developing innovative treatments for cancer and other diseases, announced today that GlaxoSmithKline’s plc (LSE/NYSE:GSK) second pivotal Phase III efficacy study of its shingles
Jul 23, 2015
Corporate Update Conference Call at 11 am ET Today LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immunology company discovering and developing innovative treatments for cancers and other diseases, today announced its financial results for the second quarter ended June 30, 2015.
Jul 20, 2015
Target Expressed on Lymphocytes and Tumors Offers Unique Advantages for Unlocking the Immune Response to Fight Cancer LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced that it has